Onychomycosis
Conditions
Brief summary
In a sham controlled double-blind trial we aim to establish the efficacy and safety of local application of laser therapy in patients with diabetes with onychomycosis and risk factors for diabetes related foot complications. Onychomycosis leads to thickened and distorted nails, which in turn leads to increased local pressure. The combination of onychomycosis and neuropathy or peripheral arterial disease (PAD) increases the risk of developing diabetes related foot complications. Usual care for high-risk patients with diabetes and onychomycosis is completely symptomatic with frequent skiving and clipping of the nails. No effective curative local therapies exist and systemic agents are often withheld due to concerns for side effects and interactions. Aim: The primary aim is to evaluate the efficacy of 4 sessions N-YAG 1064nM laser application on the one-year clinical and microbiological cure rate in a randomised, double-blinded sham-controlled design with blinded outcome assessment. Study population: Patients with diabetes mellitus, with an increased risk for diabetic foot ulcers. Intervention: local laser treatment from a podiatrist and the other group receives treatment according to a control procedure. The laser procedure will be performed as a sham procedure by a second podiatrist. Main study parameters/endpoints: The effect of 4 sessions of laser therapy on cure rate (clinical and microbiological) after one year.
Detailed description
Setting of the study: Hospital, outpatient departments (Foot clinic, Isala, Zwolle) Inclusion criteria: Patients with clinical suspicion and microbiologic confirmation of onychomycosis , diagnosis of T1DM or T2DM, 18 years or older, at risk for diabetic foot ulcers defined by a modified Simm's classification score 1 or 2 with either neuropathy or PAD, nail involvement of at least 25% of the target nail. Exclusion criteria: no microbiologic confirmation, Simms' classification score 3, the presence or history of diabetic foot ulcers, ischemic pain, ankle brachial index \< 0.9, patients receiving dialysis, severe renal insufficiently (eGFR below 30 ml/min), a documented toe pressure below 50 mmHg, use of systemic or topical antifungal agents 3 months prior to inclusion, use of immunosuppressive drugs, presence of psoriasis, lichen planus, or other abnormalities that could result in clinically abnormal toenails, a history of epilepsy and insufficient knowledge of the Dutch language. Patients with a dark skin color (Fitzpatrick 4 and 5) are excluded since dark skin color is associated with dark nails, which theoretically leads to increased temperatures during laser application
Interventions
DEVICENd:YAG laser pulse therapy
DEVICESham procedure
Sham procedure
Sponsors
Medical Research Foundation, The Netherlands
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diabetes * Over 18 years old * Clinically suspicion with microbiologic confirmation of onychomycosis * Patient is at risk for diabetic foot ulcers defines as Simms score 1, 2 .
Exclusion criteria
* Patients without the microbiological confirmation of fungal nail infection * Patients with an active or history of a diabetic foot ulcer * Patients who used systemic or topical anti fungal agents during the preceding 3 months * Patients with ischemic rest pain * Patients with ankle brachial index \< 0.9 * Patients with a documented toe pressure below 50 mmHg * Patients receiving dialysis, severe renal insufficiently (eGFR below 30 ml/min) * Patients with an insufficient knowledge of the Dutch language to understand requirements of the study * Patients with a dark skin color (Fitspatrick 4 and 5) * Patients who uses immunosuppressive medication * Patient suffering from nail psoriasis , lichen planus, or other abnormalities that could result in clinically abnormal toenails.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| complete cure of the target nail | outcome measured after 1 year | after one year the clinical and microbiological cure rate of the target nail will be compared with usual care in the placebo group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete clinical cure of the target nail | outcome measured after 1 year | Complete cure is defined as a completely normal nail, or negative microbiological results in case minor abnormalities are present. |
| Markedly clinically improved target nail | outcome measured after 1 year | A markedly improved nail is defined as a nail with less than 10% abnormalities without hyperkeratosis after 52 weeks in nails that were affected more than 10% of the surface area. |
| Onychomycosis severity index below 6 (in patients with scores >6 at study entry) of the target nail | outcome measured after 1 year | — |
| Microbiological cure of the target nail | outcome measured after 1 year | Patient with a negative microbiologic results of the target nail at week 52 will be regarded as having a microbiological cure. Patients with negative microbiological results at week 30 and positive microbiologic results at week 52 will be regarded as having a second infection. Patients with positive microbiologic results (with the same species) at week 30 and positive results at week 52 (the same species) will be regarded as treatment failure. |
| Change in quality of life | outcome measured after 1 year | WHO-5 and NailQol questionnaires are taken at baseline and week 52. Translated disease specific questionnaire; NailQol |
| Change surface healthy target nail / all clinically infected toes patients free of hyperkeratosis | outcome after 52 weeks | — |
| Complete clinical cure of all affected toes | outcome measured after 1 year | — |
Countries
Netherlands
Outcome results
None listed